Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities
Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …
Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Q Wu, MZ Dudley, X Chen, X Bai, K Dong, T Zhuang… - BMC medicine, 2021 - Springer
Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines
V Naranbhai, WF Garcia-Beltran… - The Journal of …, 2022 - academic.oup.com
Background Understanding immunogenicity and effectiveness of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. Methods …
syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. Methods …
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a …
S Toback, E Galiza, C Cosgrove, J Galloway… - The Lancet …, 2022 - thelancet.com
Background The safety and immunogenicity profile of COVID-19 vaccines when
administered concomitantly with seasonal influenza vaccines have not yet been reported …
administered concomitantly with seasonal influenza vaccines have not yet been reported …
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26. COV2. S
DJ Barbeau, JM Martin, E Carney, E Dougherty… - npj Vaccines, 2022 - nature.com
Abstract SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26. COV2. S received
emergency use authorization by the US Food and Drug Administration in 2020/2021 …
emergency use authorization by the US Food and Drug Administration in 2020/2021 …
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label …
S Wu, J Huang, Z Zhang, J Wu, J Zhang… - The Lancet Infectious …, 2021 - thelancet.com
Background SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …
intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the …
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
R Bos, L Rutten, JEM van der Lubbe, MJG Bakkers… - npj Vaccines, 2020 - nature.com
Abstract Development of effective preventative interventions against SARS-CoV-2, the
etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS …
etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS …
[PDF][PDF] Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants …
F Zhu, P Jin, T Zhu, W Wang, H Ye, H Pan, L Hou… - Clin Infect …, 2021 - scholar.archive.org
Accepted Manuscript Page 1 Accepted Manuscript © The Author(s) 2021. Published by Oxford
University Press for the Infectious Diseases Society of America. All rights reserved. For …
University Press for the Infectious Diseases Society of America. All rights reserved. For …
[HTML][HTML] Emergency use authorization of Covid vaccines—safety and efficacy follow-up considerations
PR Krause, MF Gruber - New England Journal of Medicine, 2020 - Mass Medical Soc
Emergency Use Authorization of Covid Vaccines A median 2-month follow-up after
completion of an investigational Covid-19 vaccine regimen is necessary to provide safety …
completion of an investigational Covid-19 vaccine regimen is necessary to provide safety …
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused …
C Ma, W Sun, T Tang, M Jia, Y Liu, Y Wan, J Han… - Vaccine, 2022 - Elsevier
Background In partial response to the coronavirus disease 2019 (COVID-19) pandemic,
countries around the world are conducting large-scale vaccination campaigns. Real-world …
countries around the world are conducting large-scale vaccination campaigns. Real-world …